کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2407317 | 1103121 | 2007 | 8 صفحه PDF | دانلود رایگان |

Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95%CI: €28,699 to €42,929) and €23,361, respectively (95%CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.
Journal: Vaccine - Volume 25, Issue 3, 5 January 2007, Pages 458–465